Pharma
Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST
Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization
According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.
Read
Commented by André Will-Laudien on September 28th, 2023 | 08:05 CEST
Attention: Extended correction - Buy the right stocks now! Bayer, Viva Gold, TUI, and BASF are on the list!
Higher inflation and rising interest rates - this connection should be clear to investors. The interest rate level in Germany has moved from negative territory to 2.77% in the 10-year range, but stocks continued to rise cheerfully. The party led to all-time highs of 16,528 points in July, but the fundamental situation of the companies deteriorated in parallel. Only after repeated warnings from the US Federal Reserve did the explosive NASDAQ also enter a correction. And it continues. Yesterday, the CEO of US investment bank JPMorgan, Dimon, warned that the world may not be prepared for 7% capital market interest rates. He and Dr. Jens Erhardt, the CEO of the asset management company DJE, warn of stronger setbacks on the stock markets. Some stocks have already undergone a strong correction. Here is a brief overview.
Read
Commented by Nico Popp on September 27th, 2023 | 07:10 CEST
Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics
High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!
Read
Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST
Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets
Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.
Read
Commented by Juliane Zielonka on September 14th, 2023 | 08:05 CEST
Almonty Industries, Covestro, Bayer AG - Which stocks are taking off?
Energy, pharmaceuticals and defence are the performance candidates of the hour. To support further economic growth, countries like South Korea and France are turning to nuclear power, which requires the metal tungsten. Almonty Industries, which has specialized in the mining and processing of this rare metal since 2009, is particularly eye-catching here. The current takeover talks of the DAX-listed group Covestro show how valuable know-how can be. The Abu Dhabi-based oil company Adnoc is very interested in Covestro's specialist knowledge of plastics for e-mobility, building insulation and adhesives. Bayer AG also demonstrates significant expertise. Researchers at its US subsidiary BlueRock Therapeutics have achieved a breakthrough in treating Parkinson's disease. Find out which shares are now taking off here.
Read
Commented by Nico Popp on September 13th, 2023 | 08:30 CEST
Biotech: Poison cocktail or miracle cure? Defence Therapeutics, MorphoSys, Pfizer
Biotech stocks represent both light and dark. At the end of 2020, BioNtech turned the tide of the pandemic with its Comirnaty vaccine. But many shareholders have also had to endure losses. An example of a loss-maker is the share of the SDAX stock MorphoSys. Between 2020 and 2022, the share lost more than 80%. But what were the reasons for the decline? Are there biotech companies that offer better prospects? We shed light on three stocks from the biotech and healthcare sectors.
Read
Commented by Stefan Feulner on September 7th, 2023 | 08:00 CEST
Biotech with tailwind - Newron Pharmaceuticals, Defence Therapeutics, BioNTech
There is a lot of activity in the biotechnology sector, even though the broadly diversified Nasdaq Biotech Index reflects this with a performance of only 1% since the beginning of the year. In addition to the increasing number of acquisitions by Big Pharma, promising technologies from second-tier companies are performing extremely well. Furthermore, the surging COVID-19 statistics are instilling hope in vaccine producers as they aim to revive their slumping sales.
Read
Commented by Fabian Lorenz on August 30th, 2023 | 08:30 CEST
Better than Nel & Co.? Megatrend shares Redcare Pharmacy and Cantourage Group recommended as buy
Hydrogen has electrified investors for years. But pure-plays like Plug Power and Nel & Co. are struggling to get their numbers in order and are far from profitable business models. As a result, these shares are not much fun at the moment, and analysts see further downside potential. In such a situation, it is worth taking a look at other megatrend stocks. Redcare Pharmacy (formerly Shop Apotheke) is benefiting from online pharmacy and e-prescription trends. The share has already more than doubled this year. Investors can profit from the cannabis trend with the German Cantourage Group. The Company is growing strongly and the share price has come to rest (before the storm). Both shares are recommended to buy by analysts.
Read
Commented by Nico Popp on August 30th, 2023 | 07:00 CEST
Course Rockets of Yesterday - and Tomorrow: Innocan Pharma, BioNTech, Cardiol Therapeutics
According to the information service IQVIA, dietary supplements generate almost EUR 3 billion in sales in Germany - and the trend is rising. More and more people are paying attention to their health and are not satisfied when the doctor says, "You are healthy." In fact, there is still a lot of upside potential for healthy people, too - for example, when it comes to reducing stress, improving sleep or strengthening the body's own defenses. Today, we highlight three stocks that could benefit from increased health awareness.
Read
Commented by André Will-Laudien on August 23rd, 2023 | 07:00 CEST
Climate change or just a heat wave? - BioNTech, Cardiol Therapeutics, and Redcare Pharmacy deliver!
Whether this consistently warm summer already documents a pronounced climate change is questionable. The older ones among us remember that there were already very hot summers before and that even in the last 30 years, there was rarely snow at Christmas. However, human life is simply too short for significant conclusions. Therefore, long-term weather records have to be consulted. There will probably be a slight increase in average temperatures, but we will get little information about when the next ice age will hit us. For many politicians, the current weather trends fit perfectly into the chain of arguments in favor of radical legislative proposals. Perhaps, however, the caprices of the weather are only the offshoots of the approaching El Nino. The stock market also follows changing trends; after the flood, an ebb could now be imminent. Selection remains key!
Read